Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) - Total Liabilities
Based on the latest financial reports, Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) has total liabilities worth Rs-2.76 Billion INR (≈ $-29.87 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Jagsonpal Pharmaceuticals Limited's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Jagsonpal Pharmaceuticals Limited - Total Liabilities Trend (2006–2026)
This chart illustrates how Jagsonpal Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Jagsonpal Pharmaceuticals Limited's balance sheet.
Jagsonpal Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of Jagsonpal Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Imarketkorea
KO:122900
|
Korea | ₩891.72 Billion |
|
Jaeren Sparebank
OL:JAREN
|
Norway | Nkr18.13 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩92.52 Billion |
|
Catella AB (publ)
ST:CAT-B
|
Sweden | Skr2.18 Billion |
|
BANK OF JIUJIANG H YC1
F:BJ8
|
Germany | €474.81 Billion |
|
Open Lending Corp
NASDAQ:LPRO
|
USA | $161.72 Million |
|
Digital Asset Acquisition Corp.
NASDAQ:DAAQ
|
USA | $6.94 Million |
|
AVITA Medical Inc
F:51KB
|
Germany | €74.13 Million |
Liability Composition Analysis (2006–2026)
This chart breaks down Jagsonpal Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | N/A | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jagsonpal Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jagsonpal Pharmaceuticals Limited (2006–2026)
The table below shows the annual total liabilities of Jagsonpal Pharmaceuticals Limited from 2006 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs405.05 Million ≈ $4.38 Million |
+5.73% |
| 2025-03-31 | Rs383.10 Million ≈ $4.14 Million |
+29.09% |
| 2024-03-31 | Rs296.76 Million ≈ $3.21 Million |
-17.70% |
| 2023-03-31 | Rs360.56 Million ≈ $3.90 Million |
-4.10% |
| 2022-03-31 | Rs375.99 Million ≈ $4.07 Million |
-11.06% |
| 2021-03-31 | Rs422.73 Million ≈ $4.57 Million |
+17.68% |
| 2020-03-31 | Rs359.21 Million ≈ $3.88 Million |
+14.72% |
| 2019-03-31 | Rs313.11 Million ≈ $3.39 Million |
-1.44% |
| 2018-03-31 | Rs317.68 Million ≈ $3.44 Million |
-2.84% |
| 2017-03-31 | Rs326.97 Million ≈ $3.54 Million |
-46.32% |
| 2016-03-31 | Rs609.17 Million ≈ $6.59 Million |
+3.61% |
| 2015-03-31 | Rs587.94 Million ≈ $6.36 Million |
+1.95% |
| 2014-03-31 | Rs576.68 Million ≈ $6.24 Million |
+5.56% |
| 2013-03-31 | Rs546.30 Million ≈ $5.91 Million |
-5.21% |
| 2012-03-31 | Rs576.30 Million ≈ $6.23 Million |
+31.56% |
| 2011-03-31 | Rs438.04 Million ≈ $4.74 Million |
+22.81% |
| 2010-03-31 | Rs356.69 Million ≈ $3.86 Million |
-16.29% |
| 2009-03-31 | Rs426.09 Million ≈ $4.61 Million |
-22.84% |
| 2008-03-31 | Rs552.21 Million ≈ $5.97 Million |
-26.36% |
| 2007-03-31 | Rs749.83 Million ≈ $8.11 Million |
+5.14% |
| 2006-03-31 | Rs713.18 Million ≈ $7.71 Million |
-- |
About Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. … Read more